HCV Genotype 1 Infection: IFN-Free Treatment with Direct-Acting Antivirals Available in 2015

详细信息    查看全文

• 作者：Marc Bourlière ; Tarik Asselah
• 关键词：Sofosbuvir ; Daclatasvir ; Paritaprevir ; Ombitasvir ; Ledipasvir ; Elbasvir ; Grazoprevir ; Dasabuvir
• 刊名：Current Hepatitis Reports
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：14
• 期：4
• 页码：260-266
• 全文大小：259 KB
• 参考文献：1.Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36(5 Suppl 1):S47-6.CrossRef PubMed
  2.Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-a, non-B viral hepatitis genome. Science. 1989;244(4902):359-2.CrossRef PubMed
  3.Asselah T, Marcellin P. Direct acting Antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012;32 Suppl 1:88-02.CrossRef PubMed
  4.Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell. 1996;87(2):343-5.CrossRef PubMed
  5.Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol. 1997;4(6):463-.CrossRef PubMed
  6.Estrabaud E, Vidaud M, Marcellin P, et al. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol. 2012;57(5):1110-5.CrossRef PubMed
  7.Schinazi R, Halfon P, Marcellin P, et al. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34 Suppl 1:69-8.CrossRef PubMed
  8.Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55(1):192-06.CrossRef PubMed
  9.Pawlotsky JM. New hepatitis C therapies. Semin Liver Dis. 2014;34(1):7-.CrossRef PubMed
  10.Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving Pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122-.CrossRef PubMed
  11.Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-3.CrossRef PubMed
  12.Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-8.CrossRef PubMed
  13.Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-8.CrossRef PubMed
  14.Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-3.CrossRef PubMed
  15.Osinusi A, Townsend K, Nelson A, et al. Use of sofosbuvir / ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV. J Hepatol. 2014;60(suppl):S7.CrossRef
  16.Gane EJ, Hyland RH, An D, et al. Sofosbuvir / ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients and genotype-1 patients with prior sofosbuvir treatment experienced. J Hepatol. 2014;60(suppl):S3-.CrossRef
  17.Osinusi A, Marti M, Townsend K, et al. Retreatment of relapsers to sofosbuvir / ribavirin with sofosbuvir / ledipasvir: complete and rapid virologic suppression by week 4. J Hepatol. 2014;60:S5-.CrossRef
  18.Everson GT, Tran TT, Towner WJ, et al. Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir-?GS-5816 for 12 weeks in treatment naive patients with genotype 1- HCV patients. J Hepatol. 2014;60(Suppl):S46.CrossRef
  19.Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to Pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756-5.CrossRef PubMed
  20.Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211-1.CrossRef PubMed
  21.Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir / ledipasvir fixed dose combination with or without ribavirin: the ELECTRON trial. Hepatology. 2013;58(Suppl):243A.
  22.Kohli A, Sims Z, Marti M, et al. Combination oral hepatitis C antiviral therapy for 6 or 12 weeks: results of the SYNERGY trial (Abstract). Programs and abstracts of the 21st Conference on Retroviruses and Opportunistic infections, 3- March 2014, Boston US Abstract 27 LB. 2014.
  23.Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-2.CrossRef PubMed
  24.Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-03.CrossRef PubMed
  25.Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-2.Cros
• 作者单位：Marc Bourlière (1)
  Tarik Asselah (2)
  
  1. Department of Hepato-Gastroenterology, Hospital Saint Joseph, Marseilles, France
  2. Hepatology Department, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, 100 Bd du Général Leclerc, 92110, Clichy, France
  
• 刊物主题：Hepatology;
• 出版者：Springer US
• ISSN：1541-0706

文摘

There is a revolution in the treatment of chronic hepatitis C with several oral regimen with direct-acting antivirals (DAAs) being developed, increasing sustained virological success rates and shortened treatment duration. In 2014-015, combinations of DDAs with additive potency that lack cross-resistance and with a good safety profile may provide new regimens to make hepatitis C virus (HCV) the first chronic viral infection eradicated worldwide. The aim of this review is to summarize results from approved or available complete phase III clinical trials obtained with oral DAAs combination, regimen available in 2015 in several countries for genotype 1 patients. Keywords Sofosbuvir Daclatasvir Paritaprevir Ombitasvir Ledipasvir Elbasvir Grazoprevir Dasabuvir